<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29957">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716714</url>
  </required_header>
  <id_info>
    <org_study_id>KSSCLK2014-01</org_study_id>
    <nct_id>NCT02716714</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Ingenol Mebutate Gel 0.015% &amp; 0.05% in Actinic Keratosis</brief_title>
  <official_title>A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp &amp; 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the efficacy and safety of ingenol mebutate gel 0.015% on face and scalp
      &amp; 0.05% on trunk and extremities in Korean patient with actinic keratosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mechanism of action of ingenol mebutate for actinic keratosis(AK) treatment involves a
      rapid induction of necrosis followed by neutrophil-mediated, antibody-dependent cellular
      cytotoxicity (ADCC) of residual lesion. As the ingenol mebutate infiltrates the cell
      membrane, it increases intracellular Ca2+ concentration which leads to mitochondrial
      swelling and disruption of mitochondrial membrane within hours. The release of
      intra-mitochondrial Ca2+ into the cytoplasm leads to depletion of adenosine triphosphate
      (ATP) and a rapid induction of cell death by necrosis. This process occurs within 1 hour of
      application, which explains why the treatment period requires only 2 or 3 days of treatment.
      As the next phase, the cellular necrosis is accompanied by a robust inflammatory response
      through the release of proinflammatory cytokines from skin cells and tumor cells undergoing
      necrosis. The release of these proinflammatory cytokines into the dysplastic cells mediates
      the process of neutrophil recruitment through paracrine signaling and activation of
      endothelial cells. Here, the neutrophil mediated ADCC occurs, where activated neutrophils
      attach to the fragment, crystallized (Fc) parts of antibodies of dysplastic cells and
      destroys the residual dysplastic epidermal cells. In this way, the ingenol mebutate
      eradicates any residual tumor cells and prevents recurrence of actinic keratosis.As
      described above, the rapid effect and dual mechanism of action of ingenol mebutate gel
      allows not only a short-course therapy (2 or 3 days of application) for the elimination of
      actinic keratosis but also, the benefit for eradication of any residual lesions preventing
      the recurrence and the progression of AK into squamous cell carcinoma (SCC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clearance (CC) rate of Actinic Keratosis (AK) lesions in the selected treatment area assessed by investigator</measure>
    <time_frame>at Day 57 (Visit 6)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change of the number of AK lesions in the selected treatment area assessed by investigator</measure>
    <time_frame>at Day 57 (Visit 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Complete Clearance rate in Completed Clearance group assessed by investigator</measure>
    <time_frame>at 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>at 6 months</time_frame>
    <description>Number of subjects with recurrent AK lesions assessed by investigator at Month 6 among CC group / number of subjects in CC group who have completed the follow-up till Month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of the number of AK lesions in the selected treatment area of CC group assessed by investigator.</measure>
    <time_frame>at 6 Months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by Skindex-29 which is composed of 29 items categorized into symptom, emotion, and function in CC group. The subject self-administers the survey.</measure>
    <time_frame>at Day 29 and 57 from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigator evaluates the global improvement as in cosmetic aspects of the subject using 5-scales (much better-better-no change-worse-much worse) in each items of Cosmetic Outcomes Assessment (COA).</measure>
    <time_frame>at Day 29, 57 and Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication (TSQM )is a self-administered survey which evaluates patient's treatment satisfaction and it is composed of 14 items with 4 domains of effectiveness, side effect, convenience and global satisfaction.</measure>
    <time_frame>at Day 29, 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>at 6 months</time_frame>
    <description>Among the subjects in CC group, the median recurrence time with 95% CI using Kaplan-Meier method</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Type of new treatment method used for AK on the selected treatment area by treatment response group (CC group/Non-CC group)</measure>
    <time_frame>from Day 57 to 6 months</time_frame>
    <description>CC group If there is the recurrence in the lesion within the selected treatment area, lesion-directed treatment may be performed at the judgment of the investigator. The lesion-directed treatment includes cryotherapy, laser therapy, curettage and excision and biopsy is also permitted for the purpose of diagnosis.
Non-CC group Depending on the judgment of the investigator, all pharmaceutical/non-pharmaceutical treatment/procedure are available for the selected treatment area.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>ingenol mebutate gel 0.015%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Applied on face and scalp for three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ingenol mebutate gel 0.05%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Applied on trunk and extremities for two days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ingenol mebutate gel 0.015%</intervention_name>
    <description>-Face or Scalp arm (Referred to Face/Scalp arm): Apply ingenol mebutate gel 0.015% once daily for 3 consecutive days</description>
    <arm_group_label>ingenol mebutate gel 0.015%</arm_group_label>
    <other_name>Picato® gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ingenol mebutate gel 0.05%</intervention_name>
    <description>-Trunk or Extremities arm (Referred to Trunk/Extremities arm): Apply ingenol mebutate gel 0.05% once daily for 2 consecutive days</description>
    <arm_group_label>ingenol mebutate gel 0.05%</arm_group_label>
    <other_name>Picato® gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged ≥ 19 years

          2. Histopathologically diagnosed AK patients with at least 1 macroscopic and discrete
             lesion within a contiguous 25 cm2 (e.g. 5 cm x 5 cm) of treatment area

          3. The treatment area including the lesion must be accessible to apply the
             investigational product. However, the lesions on lips, mucosa, outer ear (concha) and
             those around eyes are excluded.

          4. Subjects who signed the written informed consent prior to perform any study-related
             procedures or assessments, including photographs of their treatment area for
             documentation and efficacy assessment.

        Exclusion Criteria:

          1. Hypersensitivity to any components of the investigational product

          2. History or evidence of skin conditions that could interfere with evaluation of the
             investigational product(e.g., eczema, unstable psoriasis, xeroderma pigmentosa,
             inflammatory or infectious disease around the selected treatment area)

          3. Unhealed wound within 5 cm, or basal cell carcinoma or squamous cell carcinoma within
             10 cm from the selected treatment area.

          4. Subjects who received or expected to receive any of the following pharmacotherapy and
             non-pharmacotherapy or procedures during the treatment and follow-up period

          5. Subjects who have following disorder or abnormal laboratory result

          6. Pregnant, lactating, and childbearing potential women who are unwilling to practice
             effective contraception; for example, oral contraceptives, hormonal methods,
             placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier
             methods (i.e., condom or occlusive cap with spermicidal
             foam/gel/film/cream/suppository), male sterilization, and abstinence.

          7. Subjects who previously underwent another clinical trial within 30 days or 5-times
             the half-life of previous investigational product prior to baseline (the longer
             period of time must be considered).

          8. Other conditions by investigator's discretion to be inappropriate for this clinical
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilhwan Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan-si</city>
        <state>Gyeonggi-do</state>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.nice.org.uk/guidance/csgstim/resources/improving-outcomes-for-people-with-skin-tumoursincluding-melanoma-the-manual-2006-guidance2</url>
    <description>National Institute for Clinical Excellence. Guidance on Cancer Services:Improving outcomes for people with skin tumours including melanoma. The manual. February 2006.</description>
  </link>
  <results_reference>
    <citation>Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol. 1997 Apr;36(4):650-3. Review.</citation>
    <PMID>9092763</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmitt JV, Miot HA. Actinic keratosis: a clinical and epidemiological revision. An Bras Dermatol. 2012 May-Jun;87(3):425-34. Review.</citation>
    <PMID>22714759</PMID>
  </results_reference>
  <results_reference>
    <citation>Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42. Review.</citation>
    <PMID>9627707</PMID>
  </results_reference>
  <results_reference>
    <citation>Flohil SC, van der Leest RJ, Dowlatshahi EA, Hofman A, de Vries E, Nijsten T. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Invest Dermatol. 2013 Aug;133(8):1971-8. doi: 10.1038/jid.2013.134. Epub 2013 Mar 19.</citation>
    <PMID>23510990</PMID>
  </results_reference>
  <results_reference>
    <citation>Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol. 2007 Sep;46(9):895-904. Review.</citation>
    <PMID>17822489</PMID>
  </results_reference>
  <results_reference>
    <citation>Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7. Review.</citation>
    <PMID>10607349</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim HS, Cho EA, Bae JM, Yu DS, Oh ST, Kang H, Park CJ, Lee JD, Lee JY, Kim SY, Kim HO, Park YM. Recent trend in the incidence of premalignant and malignant skin lesions in Korea between 1991 and 2006. J Korean Med Sci. 2010 Jun;25(6):924-9. doi: 10.3346/jkms.2010.25.6.924. Epub 2010 May 24.</citation>
    <PMID>20514316</PMID>
  </results_reference>
  <results_reference>
    <citation>Slaper H, Velders GJ, Daniel JS, de Gruijl FR, van der Leun JC. Estimates of ozone depletion and skin cancer incidence to examine the Vienna Convention achievements. Nature. 1996 Nov 21;384(6606):256-8.</citation>
    <PMID>8918873</PMID>
  </results_reference>
  <results_reference>
    <citation>Nelson CG. Diclofenac gel in the treatment of actinic keratoses. Ther Clin Risk Manag. 2011;7:207-11. doi: 10.2147/TCRM.S12498. Epub 2011 Jun 15.</citation>
    <PMID>21753882</PMID>
  </results_reference>
  <results_reference>
    <citation>Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H; European Skin Academy.. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol. 2008 Nov-Dec;18(6):651-9. doi: 10.1684/ejd.2008.0514. Epub 2008 Oct 27.</citation>
    <PMID>18955209</PMID>
  </results_reference>
  <results_reference>
    <citation>Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, Katsamas J. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009 Jun;60(6):934-43. doi: 10.1016/j.jaad.2009.01.008.</citation>
    <PMID>19467365</PMID>
  </results_reference>
  <results_reference>
    <citation>Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One. 2014 Jun 3;9(6):e96829. doi: 10.1371/journal.pone.0096829. eCollection 2014.</citation>
    <PMID>24892649</PMID>
  </results_reference>
  <results_reference>
    <citation>Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004 May;50(5):714-21.</citation>
    <PMID>15097955</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012 Mar;66(3):486-93. doi: 10.1016/j.jaad.2010.12.038. Epub 2011 Nov 4. Review.</citation>
    <PMID>22055282</PMID>
  </results_reference>
  <results_reference>
    <citation>Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012 Mar 15;366(11):1010-9. doi: 10.1056/NEJMoa1111170.</citation>
    <PMID>22417254</PMID>
  </results_reference>
  <results_reference>
    <citation>Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013 Jun;149(6):666-70. doi: 10.1001/jamadermatol.2013.2766.</citation>
    <PMID>23553119</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 11, 2016</lastchanged_date>
  <firstreceived_date>January 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Il-Hwan Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Korean</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be made within 6months of study completion.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
